WCLC 2025 - Posters & ePosters-P1.11.82 Study of THIO Sequenced With Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-Resistant aNSCLC: Improvement in PFS

P1.11.82 Study of THIO Sequenced With Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-Resistant aNSCLC: Improvement in PFS

Asset Subtitle

Victor Zaporojan

Meta Tag

Speaker Victor Zaporojan

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy